Octagon Capital Advisors LP Cardiff Oncology, Inc. Transaction History

Octagon Capital Advisors LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $2.07 Million - $7.12 Million	-982,753 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.65 - $10.04 $2.21 Million - $3.34 Million	332,753 Added 51.19%	982,753 $6.54 Million
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $7.81 Million - $16.1 Million	650,000 New	650,000 $11.7 Million

101

11.8M

823K

78K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $139M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Octagon Capital Advisors LP with notifications on news.